After Plunging -20% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
- Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 11/15/2024
|
After Plunging -15.92% in 4 Weeks, Here's Why the Trend Might Reverse for Gossamer Bio (GOSS)
- The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 11/14/2024
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective November 8, 2024, to two new non-executive employees of non-qualified stock opti.
- 11/11/2024
|
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
- Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago.
- 11/07/2024
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective October 4, 2024, to five new non-executive employees of non-qualified stock opti.
- 10/07/2024
|
3 Penny Stocks To Buy With Just $50
- Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.
- 09/15/2024
|
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
- Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025.
- 09/10/2024
|
Gossamer Bio (GOSS) Q2 Earnings and Revenues Lag Estimates
- Gossamer Bio (GOSS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.45 per share a year ago.
- 08/12/2024
|
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
- Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.
- 06/25/2024
|
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
- Do you have any penny stocks in your portfolio? If you don't, you might want to consider it with any speculative money sitting on the sidelines.
- 06/13/2024
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective June 5, 2024, to one new non-executive employee of non-qualified stock option aw.
- 06/07/2024
|
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California. Details.
- 05/14/2024
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 8, 2024, to three new non-executive employees of non-qualified stock option.
- 05/10/2024
|
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment
- Gossamer Bio said on Monday it will collaborate with Chiesi Group to develop and commercialize its drug seralutinib in multiple indications related to blood pressure conditions.
- 05/06/2024
|
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
- SAN DIEGO, Calif. & PARMA, Italy--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (“Gossamer”) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A (“Chiesi Group”), an international, research-focused biopharmaceutical group, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib. This glob.
- 05/06/2024
|
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
- SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine journal. The paper, titled "Seralutinib in Adults with Pulmonary Arterial Hypertensio.
- 05/03/2024
|
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors. Dr. Nathan is Medical Director of Inova's Advanced Lung Disease Program and Lung Transpla.
- 03/12/2024
|
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
- Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
- 03/07/2024
|
GOSS Stock Earnings: Gossamer Bio Meets EPS for Q4 2023
- Gossamer Bio (NASDAQ: GOSS ) just reported results for the fourth quarter of 2023. Gossamer Bio reported earnings per share of -21 cents.
- 03/05/2024
|
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided a business update. “We were thrilled to enroll the first patient in the registrational PROSERA Study last year, and we are pleased with the pace of site activati.
- 03/05/2024
|
7 Micro-Cap Stocks That Could Majorly Surprise Investors
- Practically by default, your typical financial advisor will steer you clear of micro-cap stock surprises in favor of large-capitalization enterprises. Yes, the blue chips are reliable and dependable but this underlying predictability often comes at a cost: usually, you're not going to get rich off of them.
- 01/31/2024
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective January 5, 2024, to two new non-executive employees of non-qualified stock option awards to purchase up to an aggregate of 212,500 shares of the Company's com.
- 01/08/2024
|
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients. Sera.
- 12/13/2023
|
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it has granted stock options to Bob Smith, Gossamer's newly appointed Chief Commercial Officer. The Compensation Committee of Gossamer's Board of Directors approved the grant, effective December 4, 2023, to Mr. Smith of a stock option to purchase 1.
- 12/05/2023
|
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. “We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history,” said Faheem Hasnain, Chairman, Co-Founder and CEO of Gos.
- 12/05/2023
|
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. “Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Goss.
- 11/29/2023
|
11 Top Penny Stocks To Buy Now According To Insiders
- Ever wonder what signals to look for in the stock market today? Let's talk about insider buying – a goldmine of clues that could lead you to the next prospect to add to your list of penny stocks to watch.
- 11/17/2023
|
5 Penny Stocks To Buy Now According To Insiders
- Penny stocks are often priced under $5 per share. They attract traders seeking big gains.
- 11/15/2023
|
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced its financial results for the third quarter ended September 30, 2023, and provided a business update. “We are pleased with the progress our team has made with the launch of the seralutinib Phase 3 PROSERA Study. With sites opening up across the globe, w.
- 11/09/2023
|
Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs
- SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary H.
- 10/03/2023
|
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional respiratory imaging, or FRI, sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with PAH will be presented at the European Respiratory Society International Congress 2023. Dr. Roham Zamanian, Profes.
- 09/07/2023
|
Gossamer Bio stock struggles from lack of near-term catalysts: analysts
- Shares of Gossamer Bio fell Thursday, and the company earned a downgrade from analysts at UBS. Citing a "lack of near-term catalysts," the firm downgraded the biopharmaceutical company to Neutral from Buy and slashed its price target to $1.25 from $8.
- 07/27/2023
|
Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it will hold a conference call with PAH experts on Tuesday, July 25th at 10 a.m. EDT. Gossamer's management team will be joined by world-renowned PAH key opinion leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White to discuss the upcoming P.
- 07/24/2023
|
Gossamer Bio: Merck's STELLAR Data Impressive, But Game Not Over For Seralutinib
- Merck's Sotatercept showed significant improvements in PAH patients in Phase 3 STELLAR trial with a primary endpoint of improvements in pulmonary vascular resistance, 6-minute walk distance, and NT-proBNP levels. Gossamer Bio's seralutinib showed clear efficacy in the Phase 2 TORREY trial, albeit not meeting expectations, and is moving forward with a revised Phase 3 trial.
- 04/02/2023
|
10 Top Penny Stocks To Watch With High Short Interest This Week
- More short squeeze penny stocks to watch before February 2023. The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/31/2023
|
Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore
- Gossamer's TORREY showed stat sig PVR improvement, but the 6MWD was under what investors were hoping for; this led to a +70% decline in share price. Seralutnib is entering phase 3 with an adapted design (with more severe patients); although the success is less clear, any positive surprises can lead to a meaningful stock rally.
- 01/30/2023
|
4 Penny Stocks To Watch With High Short Interest In January 2023
- Are these penny stocks ready to squeeze? The post 4 Penny Stocks To Watch With High Short Interest In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/27/2023
|
Gossamer Bio (GOSS) Upgraded to Buy: What Does It Mean for the Stock?
- Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 01/04/2023
|
Gossamer Bio (GOSS) Loses -13.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Gossamer Bio (GOSS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- 01/04/2023
|
3 Short Squeeze Penny Stocks To Watch Before 2023
- Short squeeze penny stocks to watch. The post 3 Short Squeeze Penny Stocks To Watch Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/28/2022
|
10 Top Penny Stocks To Watch With High Short Interest This Week
- Short squeeze penny stocks to buy now or avoid entirely? The post 10 Top Penny Stocks To Watch With High Short Interest This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 12/20/2022
|
Penny Stocks Vs. Blue Chips, 3 Main Differences
- Understand these key penny stocks vs. blue chips differences The post Penny Stocks Vs.
- 12/17/2022
|
Penny Stocks To Buy Now? 6 Short Squeeze Stocks To Watch
- Penny stocks to watch with higher short interest right now. The post Penny Stocks To Buy Now?
- 12/16/2022
|
Penny Stocks To Buy Now? 3 Short Squeeze Stocks To Watch
- Penny stocks to watch with higher short interest right now. The post Penny Stocks To Buy Now?
- 12/13/2022
|
Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise
- Gossamer Bio, Inc.'s lead candidate - Seralutinib, indicated for Pulmonary Arterial Hypertension - met its primary endpoint in the Phase 2 TORREY study. Nevertheless, investors dumped the stock - due to Seralutinib's perceived inferiority to Merck's Sotatercept.
- 12/08/2022
|
Gossamer Bio tumbles as hypertension drug underperforms rival product in Phase 2 trial
- Gossamer Bio Inc stock lost three quarters of its value today as the market questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial despite an upbeat assessment from the company. “We are very pleased to share that seralutinib significantly improved hemodynamic, biomarker, and right heart structural and functional measures in a heavily treated pulmonary arterial hypertension patient population,” said Faheem Hasnain, CEO of Gossamer.
- 12/06/2022
|
Why Is Gossamer Bio (GOSS) Stock Down Over 70% Today?
- Gossamer Bio (NASDAQ: GOSS ) is one of the top-trending tickers on social media today, and its shares are plunging more than 70%. The company announced that a trial of its drug for hypertension, seralutinib, had met the primary goal in a Phase 2 trial.
- 12/06/2022
|
Gossamer Bio's stock falls 64% on findings for Phase 2 study for hypertension drug
- Shares of Gossamer Bio Inc. GOSS, +2.99% plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned the performance of the company's experimental hypertension drug in a Phase 2 clinical trial. Though Gossamer said the drug, seralutinib, met the primary endpoint in a Phase 2 clinical trial, SVB Securities analyst Joseph Schwartz told investors that the therapy didn't outperform Merck & Co. Inc.'s MRK, -0.03% sotatercept.
- 12/06/2022
|
What Makes Gossamer Bio (GOSS) a New Buy Stock
- Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 11/08/2022
|
This little-known biopharma stock could rally 70%: Goldman Sachs
- Gossamer Bio Inc (NASDAQ: GOSS) is in the green on Thursday after a Goldman Sachs analyst said the stock is ready for another huge move to the upside.
- 10/20/2022
|
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy
- Does Gossamer Bio (GOSS) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 07/19/2022
|
How to Find Penny Stocks to Buy in Summer 2022
- Use these tips to find penny stocks to buy this Summer The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/16/2022
|
Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program
- Gossamer Bio Inc (NASDAQ: GOSS) shares are falling after announcing topline results from its Phase 2 SHIFT-UC Study trial of GB004 in patients with mild-to-moderate active ulcerative colitis (UC). Neither GB004 treatment arm met the primary or secondary endpoints at week 12.
- 04/25/2022
|
Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-year 2021 financial results on Thursday, March 3, 2022. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 4:30 p.m. ET on
- 02/28/2022
|
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q3 2021 Results - Earnings Call Transcript
- Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q3 2021 Results - Earnings Call Transcript
- 11/08/2021
|
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208
- SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the addition of two CNS-penetrant Bruton's tyrosine kinase (BTK) inhibitors to its product candidate pipeline. Gossamer plans to initiate first-in-human studies of the first of these candidates, GB5121, in the fourth quarter of 2021. G
- 10/11/2021
|
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Monday, October 11, 2021, at 2:30 pm ET to announce its next clinical product candidates. Gossamer management will present and discuss its forthcoming additi
- 10/07/2021
|
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that, Bryan Giraudo has been appointed Chief Operating Officer, in addition to his continued role as Chief Financial Officer. Mr. Giraudo joined Gossamer in May 2018 as its Chief Financial Officer. “Bryan has been instrumental in stren
- 09/21/2021
|
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q2 2021 Results - Earnings Call Transcript
- Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn's and Colitis Organisation
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data related to GB004 at the 2021 Virtual Congress of the European Crohn's and Colitis Organisation (ECCO), to be held virtually from July 2-3 and 8-10. On July 8, William Sandborn, M.D., will present a digital ora
- 07/07/2021
|
Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that, Richard Aranda, M.D., previously Senior Vice President and Head of Clinical Development, will be promoted to Chief Medical Officer. Dr. Aranda joined Gossamer in February 2018 with responsibilities including oversight of Clinical
- 06/21/2021
|
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
- SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Luisa Salter-Cid, Ph.D., Gossamer's Chief Scientific Officer, is resigning from Gossamer effective April 30, 2021. On that date, Laura Carter, Ph.D., currently Gossamer's Senior Vice President, Research & Translational Biology
- 04/20/2021
|
Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs
- SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs. In this role, Ms. Peterson will continue to lead Gossamer's Regulatory and Quality functions, tasked with strategizing and implementing global regulatory
- 04/16/2021
|
Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical's Razuprotafib in I-SPY COVID Trial
- SAN FRANCISCO and CINCINNATI, March 5, 2021 /PRNewswire/ -- Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio Pharmaceuticals drug, razuprotafib. Razuprotafib was chosen for testing in the I-SPY COVID...
- 03/05/2021
|
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q4 2020 Results - Earnings Call Transcript
- Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q4 2020 Results - Earnings Call Transcript
- 02/27/2021
|
Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update
- SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2020 and provided a business update. “The Gossamer team enters 2021 excited and focused on clinical trial execution,” said Faheem Hasnain, Co-Founder, Chairman an
- 02/25/2021
|
Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021
- SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-year 2020 financial results on Thursday, February 25, 2021. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 8:30 a.m. E
- 02/19/2021
|
Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Thursday, February 18, 2021 at 11:00am ET to discuss GB004, its oral HIF-1α stabilizer for the treatment of inflammatory bowel disease (IBD), including ulcer
- 02/04/2021
|
Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020
- SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will host a conference call and webcast for investors and analysts on Tuesday, December 15, 2020 at 11:00am ET to discuss GB002, its inhaled PDGFR inhibitor, for the treatment of pulmonary arterial hypertension (PAH). This webc
- 12/07/2020
|
Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer
- SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that the Company's Board of Directors has appointed Faheem Hasnain as Chief Executive Officer and President, effective immediately. Mr. Hasnain is a Co-Founder, former Chief Executive Officer, and current Chairman of Gossamer Bio. Mr.
- 11/16/2020
|
Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2020 Results - Earnings Call Transcript
- Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q3 2020 Results - Earnings Call Transcript
- 11/10/2020
|
Gossamer Bio Announces GB1275 Data Presentations at 2020 Society for Immunotherapy of Cancer Annual Meeting
- SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data relevant to GB1275 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), to be held virtually from November 9-14, 2020. This includes clinical and biomarker data from the ongoing GB1275
- 11/06/2020
|
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the second quarter 2020 and provided a corporate update.
- 08/11/2020
|
Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference
- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001 and GB002 programs at the American Thoracic Society 2020 Virtual Conference, which takes place from August 5th through 8th.
- 08/05/2020
|
Could The Gossamer Bio, Inc. (NASDAQ:GOSS) Ownership Structure Tell Us Something Useful?
- If you want to know who really controls Gossamer Bio, Inc. (NASDAQ:GOSS), then you'll have to look at the makeup of...
- 07/22/2020
|
Gossamer Bio's Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Gossamer Bio.
- 07/22/2020
|
Voloridge Investment Management LLC Takes Position in Gossamer Bio Inc (NASDAQ:GOSS)
- Voloridge Investment Management LLC purchased a new stake in Gossamer Bio Inc (NASDAQ:GOSS) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 20,459 shares of the company’s stock, valued at approximately $208,000. Several other hedge funds also recently modified […]
- 07/04/2020
|
Is Gossamer Bio, Inc. (GOSS) A Good Stock To Buy?
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]
- 07/03/2020
|
Insider Buying: Gossamer Bio Inc (NASDAQ:GOSS) CFO Purchases $25,920.00 in Stock
- Gossamer Bio Inc (NASDAQ:GOSS) CFO Bryan Giraudo acquired 2,000 shares of the company’s stock in a transaction dated Tuesday, June 23rd. The stock was purchased at an average cost of $12.96 per share, with a total value of $25,920.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is […]
- 06/26/2020
|
Gossamer Bio (NASDAQ:GOSS) Upgraded to Hold at Zacks Investment Research
- Gossamer Bio (NASDAQ:GOSS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation and […]
- 06/24/2020
|
Zacks Investment Research Downgrades Gossamer Bio (NASDAQ:GOSS) to Sell
- Gossamer Bio (NASDAQ:GOSS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, […]
- 06/19/2020
|
Gossamer Bio Inc (NASDAQ:GOSS) Shares Acquired by Alliancebernstein L.P.
- Alliancebernstein L.P. lifted its stake in shares of Gossamer Bio Inc (NASDAQ:GOSS) by 5.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,836,375 shares of the company’s stock after acquiring an additional 95,370 shares during the quarter. Alliancebernstein L.P. owned about 2.77% of […]
- 06/18/2020
|
Russell Investments Group Ltd. Lowers Holdings in Gossamer Bio Inc (NASDAQ:GOSS)
- Russell Investments Group Ltd. trimmed its holdings in Gossamer Bio Inc (NASDAQ:GOSS) by 84.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,820 shares of the company’s stock after selling 26,481 shares during the period. Russell Investments Group Ltd.’s holdings in […]
- 06/16/2020
|
Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma
- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that it is hosting a key opinion leader (KOL) call on a novel mechanism for the treatment of glaucoma on Friday, June 12, 2020 at 11:30am Eastern Time. The call will feature presentations by Dr. Paul Kaufman M.D. (University of Wisconsin) and Dr. Janey Wiggs, M.D., Ph.D. (Massachusetts Eye and Ear Infirmary and Harvard Medical School), who will discuss the current glaucoma treatment landscape and unmet medical needs, as well as the role of the Tie2 receptor in maintaining intraocular pressure.
- 06/08/2020
|
GOSS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 2, 2020 in the Class Action Filed on Behalf of Gossamer Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in ...
- 06/02/2020
|
GOSS FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020
- New York, New York--(Newsfile Corp. - June 2, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or (2) between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"). Such investors are encouraged to join ...
- 06/02/2020
|
Gossamer Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Gossamer Bio, Inc. to Contact the Firm
- New York, New York--(Newsfile Corp. - June 2, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi logoIf you invested in Gossamer stock or options between February 8, 2019 and ...
- 06/02/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Gossamer Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 2, 2020 - GOSS
- New York, New York--(Newsfile Corp. - June 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. ("Gossamer") (NASDAQ: GOSS) The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with ...
- 06/02/2020
|
GOSS FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020
- NEW YORK, NY / ACCESSWIRE / June 2, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the ...
- 06/02/2020
|
LAWSUITS FILED AGAINST GOSS, LBRT and FITB - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- NEW YORK, NY / ACCESSWIRE / June 2, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
- 06/02/2020
|
FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses to Contact the Firm
- Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
- 06/02/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GOSS, SERV and BBBY
- NEW YORK, NY / ACCESSWIRE / June 2, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 06/02/2020
|
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ...
- 06/02/2020
|
GOSS FINAL DEADLINE TODAY: Rosen, a Top Ranked Law Firm, Reminds Gossamer Bio, Inc. Investors of Important June 2 Deadline in Securities Class Action – GOSS
- NEW YORK, June 02, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Gossamer Bio, Inc. (NASDAQ: GOSS) (i) pursuant and/or.
- 06/02/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GOSS, GSX and BIDU
- NEW YORK, NY / ACCESSWIRE / June 2, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 06/02/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
- NEW YORK, NY / ACCESSWIRE / June 1, 2020 / Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS). Such investors ...
- 06/02/2020
|
SHAREHOLDER ALERT: GOSS R SRNE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / June 1, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss ...
- 06/01/2020
|
FINAL DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses to Contact the Firm
- Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
- 06/01/2020
|
GOSS FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020
- New York, New York--(Newsfile Corp. - June 1, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or (2) between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"). Such investors are encouraged to join ...
- 06/01/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Gossamer Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 2, 2020 - GOSS
- New York, New York--(Newsfile Corp. - June 1, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS)("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February 8, ...
- 06/01/2020
|
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 1, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public ...
- 06/01/2020
|
Gossamer Bio Announces Participation in Upcoming Investor Conferences
- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its participation in two upcoming investor conferences. Chief Executive Officer and Co-Founder Sheila Gujrathi, M.D., will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, at 3:00 p.m. ET and at the 41st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, at 2:10 p.m. ET.
- 06/01/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GOSS, GSX and IQ
- NEW YORK, NY / ACCESSWIRE / June 1, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders ...
- 06/01/2020
|
TUESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
- 06/01/2020
|
GOSS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020
- NEW YORK, NY / ACCESSWIRE / May 31, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the ...
- 05/31/2020
|
2-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 31, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities pursuant and/or traceable to the Company's ...
- 05/31/2020
|
FINAL DEADLINE: ROSEN, A TRUSTED AND RANKED FIRM, Encourages Gossamer Bio, Inc. Investors with Losses to Contact Firm Before Important June 2 Deadline in Securities Class Action- GOSS
- NEW YORK, NY / ACCESSWIRE / May 30, 2020 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Gossamer Bio, Inc. (NASDAQ:GOSS) (i) pursuant and/or traceable to the ...
- 05/30/2020
|
FINAL DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
- 05/30/2020
|
GOSS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 2, 2020 in the Class Action Filed on Behalf of Gossamer Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 29, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued ...
- 05/29/2020
|
FINAL DEADLINE IMMINENT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
- 05/29/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GOSS, SERV and HALL
- NEW YORK, NY / ACCESSWIRE / May 29, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders ...
- 05/29/2020
|
GOSS FINAL DEADLINE TUESDAY: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Reminds Gossamer Bio, Inc. Investors of Important June 2 Deadline in Securities Class Action – GOSS
- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Gossamer Bio, Inc. (NASDAQ: GOSS) (i) pursuant and/or traceable to the Company’s initial public offering in February 2019 (the "IPO" or "Offering"); and/or (ii) between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), of the important June 2, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Gossamer investors under the federal securities laws.
- 05/29/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Gossamer Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 2, 2020 - GOSS
- New York, New York--(Newsfile Corp. - May 29, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February ...
- 05/29/2020
|
TUESDAY DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 29, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public ...
- 05/29/2020
|
Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific Program
- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of positive safety and biomarker data at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) from its ongoing Phase 1/2 study of GB1275 in patients with selected solid tumors.
- 05/29/2020
|
CLASS ACTION UPDATE for GOSS, GSX and GRPN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / May 28, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 05/29/2020
|
FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 28, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" ...
- 05/29/2020
|
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...
- 05/29/2020
|
7 High-Risk Stocks For Market Gamblers
- Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local casino. Sports gamblers are still waiting for the return of Major League Baseball and other pro and college sports leagues.In the meantime, some gamblers are looking to get their thrills in the stock market. But as many new traders learn the hard way, placing bets on the wrong stocks can be just as costly as picking the wrong horse at the racetrack.Here are eight Bank of America buy-rated stocks that have high volatility ratings and at least 40% upside to analyst price targets.Golar LNG (NASDAQ: GLNG) Golar LNG owns and operates one of the largest independent liquid natural gas carriers and floating storage fleets in the world.Analyst Ken Hoexter says Golar is a leader in the LNG transport and energy infrastructure business, and it has advantages over many of its competitors due to its more diversified offerings. In addition, Bank of America is bullish on long-term LNG prices as more terminals in Australia, Russia and the U.S. come online this year. Hoexter says there is upside to the company's Golar Power EBITDA over the next two years.Bank of America has a Buy rating and $15 price target for GLNG stock.Gossamer Bio Inc (NASDAQ: GOSS) Gossamer Bio is a biotech company with a pipeline of clinical and preclinical drug candidates focused on immunology, inflammation and oncology.Analyst Geoff Meacham said in March that Gossamer has several clinical candidates that have the potential to have massive total addressable markets treating a wide range of common conditions, including asthma and pulmonary arterial hypertension. Meacham said the company has a long list of potential near-term catalysts ahead that could potentially de-risk the stock and generate significant upside. He said data on BG001 in asthma is likely the biggest catalyst ahead.Bank of America has a Buy rating and $26 price target for GOSS stock.See Also: 7 Sin Stocks To Buy During The Coronavirus ShutdownLexinFintech Holdings Ltd - ADR (NASDAQ: LX) Lexin Fintech is an online consumer financing platform geared toward educated young adults in China.Analyst Eddie Lueng recently said he expects the company will shift gears from user growth in the second half of 2019 to optimizing its user acquisitions in the first half of 2020 due to the pandemic. Lueng says the company has a relatively sticky user base compared to its peers, and it's also exposed to less regulatory risk. Its user base of around 5 million people is only about 5% penetration of China's educated young adult demographic.Bank of America has a Buy rating and $19.80 price target for LX stock.Millicom International Cellular SA (NASDAQ: TIGO) Millicom is a telecom provider for nearly 50 million customers in Latin America and Africa.Analyst Rodrigo Villanueva recently said management took decisive action in preparing for the economic downturn by implementing more than $100 million in cost savings, cutting between $200 million and $300 million in capex, suspending $100 million in 2020 dividend payments and pausing $150 million in buybacks. Villanuava says prioritizing liquidity and cash is the right move, and the company's subscription-based revenue should prove relatively resilient during the downturn while the stock's valuation provides long-term upside.Bank of America has a Buy rating and $56 price target for TIGO stock.GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) GW Pharmaceuticals is a biopharmaceutical company that focuses primarily on developing cannabinoid-based drugs for a wide variety of applications. GW's Epidiolex was the first ever cannabis-based medication ever approved by the FDA.Analyst Tazeen Ahmad recently said Epidiolex's label could soon expand beyond epilepsy to tuberous sclerosis complex in the U.S., while launches in countries like Germany, the UK, France, Spain and Italy are also driving near-term revenue upside. Ahmad said Epidiolex's sales trajectory up to this point has been impressive and has closely tracked the results of Bank of America's previous doctor surveys.Bank of America has a Buy rating and $230 price target for GWPH stock.NextCure Inc (NASDAQ: NXTC) NextCure is a clinical stage biotech company developing cancer treatments.Analyst Alec Stranahan recently spoke to NextCure management following Bank of America's 2020 Healthcare Conference, and Stranahan said the COVID-19 outbreak has negatively impacted enrollment of the company's ongoing NC318 Phase II testing. In addition, studies of NC410 and NC318 have also been disrupted.Given the delays, Stranahan estimated the highly anticipated Phase II NC318 data will likely now come in the first half of 2021 rather than the fourth quarter of 2020. The massive potential of NC318 and NC410 created home run potential for investors, but the inherent risk in the early-stage trial data generates inherent risk.Bank of America has a Buy rating and $62 price target for NXTC stock.SINA Corp (NASDAQ: SINA) Sina is the owner of leading online social media and wireless value-added service Weibo in China.Leung recently said Sina's ad revenue took a significant hit in the first half of 2020, but the COVID-19 outbreak likely went a long way in highlighting the value of Weibo given the government and media outlets used it to disseminate information. Leung is calling for a 1% drop in revenue in 2020, including a 10% decline in portal ads and a 9% increase in fintech revenue.Like many other stocks, Leung is anticipating a strong recovery in the second half of the year and said user monetization, advertising, membership growth and app improvements are all bullish long-term drivers.Bank of America has a Buy rating and $57 price target for SINA stock.Latest Ratings for GWPH DateFirmActionFromTo May 2020Cantor FitzgeraldMaintainsOverweight Apr 2020Northland Capital MarketsInitiates Coverage OnOutperform Mar 2020CitigroupInitiates Coverage OnBuy View More Analyst Ratings for GWPH View the Latest Analyst Ratings See more from Benzinga * Cannabis Short Sellers Down 1M In May * Cannabis Stock Rally Puts Short Sellers In The Red For 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/28/2020
|
GOSS SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020
- New York, New York--(Newsfile Corp. - May 28, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or (2) between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"). Such investors are encouraged to join ...
- 05/28/2020
|
GOSS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 2, 2020 in the Class Action Filed on Behalf of Gossamer Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 28, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in ...
- 05/28/2020
|
Gossamer Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Gossamer Bio, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - May 28, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi logoIf you invested in Gossamer stock or options between February 8, 2019 and December ...
- 05/28/2020
|
TUESDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 28, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial ...
- 05/28/2020
|
LAWSUITS FILED AGAINST GOSS, ZM and GRPN - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- NEW YORK, NY / ACCESSWIRE / May 28, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
- 05/28/2020
|
JUNE 2 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
- 05/28/2020
|
7 High-Risk Stocks For Market Gamblers
- Casinos are just starting to open back up following COVID-19 shutdowns, but it may still be a while before some gamblers are willing to venture back to Vegas or even their local...
- 05/28/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of VMW, GOSS and DNK
- NEW YORK, NY / ACCESSWIRE / May 27, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. A class action has commenced on behalf of certain shareholders in VMware, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) VMware's reporting with respect to its backlog of unfilled orders was not in compliance with all relevant accounting and disclosure requirements; (ii) the foregoing subjected the Company to a foreseeable risk of heightened regulatory scrutiny and/or investigation; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
- 05/27/2020
|
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients
- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been reached to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. Approximately 10-15% of those infected with the highly contagious SARS-CoV2 virus, the cause of COVID-19, develop ARDS with a death rate in the 2-10% range. Preclinical models, large human observational studies, and human genetic studies from leading groups worldwide have independently arrived at the concept that a vascular endothelial receptor, Tie2, may play a pivotal role in the defense against microvascular breach in acute respiratory distress syndrome (ARDS) 1-4.
- 05/27/2020
|
GOSS SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020
- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (GOSS) (1) pursuant and/or traceable to the Company’s initial public offering in February 2019 (the "IPO" or "Offering"); and/or (2) between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/goss.
- 05/27/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Gossamer Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 2, 2020 - GOSS
- New York, New York--(Newsfile Corp. - May 27, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February ...
- 05/27/2020
|
TUESDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 27, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering ...
- 05/27/2020
|
GOSS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 2, 2020 in the Class Action Filed on Behalf of Gossamer Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 27, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in ...
- 05/27/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
- Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 05/27/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GOSS, IQ and HALL
- NEW YORK, NY / ACCESSWIRE / May 26, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 05/26/2020
|
FINAL DEADLINE JUNE 2: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
- 05/26/2020
|
CLASS ACTION UPDATE for GOSS, BIDU and DNK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / May 26, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 05/26/2020
|
GOSS SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020
- NEW YORK, NY / ACCESSWIRE / May 26, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the ...
- 05/26/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Gossamer Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 2, 2020 - GOSS
- New York, New York--(Newsfile Corp. - May 26, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February ...
- 05/26/2020
|
Notice of June 2, 2020 Lead Plaintiff Deadline for Shareholders in the Gossamer Bio, Inc. Securities Class Action Lawsuit
- Robbins Geller Rudman & Dowd LLP announces that purchasers of Gossamer Bio, Inc. (NASDAQ:GOSS) common stock between February 8, 2019 and December 13, 2019 (the "Class Period"), including acquirers of Gossamer stock pursuant to the Company’s February 8, 2019 initial public offering ("IPO"), have until June 2, 2020 to seek appointment as lead plaintiff in a securities class action lawsuit. The case is captioned Kuhne v. Gossamer Bio, Inc., No. 20-cv-00649 (S.D. Cal.), and is assigned to Judge Dana M. Sabraw. The Gossamer Bio securities class action lawsuit charges Gossamer, certain of its officers and directors, and the underwriters of its IPO with violations of the Securities Exchange Act of 1934 and/or the Securities Act of 1933.
- 05/26/2020
|
CLASS ACTION UPDATE for MESA, GOSS and BIDU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / May 25, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 05/25/2020
|
JUNE 2 DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
- 05/25/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
- NEW YORK, NY / ACCESSWIRE / May 25, 2020 / Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS). Such investors ...
- 05/25/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DOYU, GOSS and BBBY
- NEW YORK, NY / ACCESSWIRE / May 25, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 05/25/2020
|
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020. If you are a shareholder who suffered a loss, click here to participate.
- 05/24/2020
|
LAWSUITS FILED AGAINST GOSS, LBRT and BIDU - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- NEW YORK, NY / ACCESSWIRE / May 24, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
- 05/24/2020
|
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
- Biotech stocks closed the week ended May 22 higher, with stray clinical readouts and COVID-19 drug- and vaccine-related news moving stocks in the sector.
Surface Oncology Inc (...
- 05/24/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
- NEW YORK, NY / ACCESSWIRE / May 23, 2020 / Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS). Such investors ...
- 05/23/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ANAB, GOSS and HALL
- NEW YORK, NY / ACCESSWIRE / May 22, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 05/22/2020
|
Shareholder Alert: Robbins LLP Announces Gossamer Bio, Inc. (GOSS) Sued for Misleading Shareholders
- Shareholder rights law firm Robbins LLP announces that a purchaser of Gossamer Bio, Inc. (NASDAQ: GOSS) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 8, 2019 and December 13, 2019, as well as violations of the Securities Act of 1933 pursuant to its February 2019 initial public offering ("IPO"). Gossamer is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapeutics. Gossamer's leading product is GB001, a DP2 antagonist drug for the treatment of asthma.
- 05/22/2020
|
GOSS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 2, 2020 in the Class Action Filed on Behalf of Gossamer Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 22, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in ...
- 05/22/2020
|
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 22, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" ...
- 05/22/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Gossamer Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 2, 2020 - GOSS
- New York, New York--(Newsfile Corp. - May 21, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with ...
- 05/21/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
- Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 05/21/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of VMW, MESA and GOSS
- NEW YORK, NY / ACCESSWIRE / May 21, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders ...
- 05/21/2020
|
FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 21, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" ...
- 05/21/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ANAB, GOSS and ZM
- NEW YORK, NY / ACCESSWIRE / May 21, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- 05/21/2020
|
SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 20, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020.
- 05/21/2020
|
GOSSAMER INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Gossamer Bio, Inc. To Contact The Firm
- NEW YORK, May 20, 2020 /PRNewswire via COMTEX/ --
NEW YORK, May 20, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is...
- 05/20/2020
|
GOSS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 2, 2020 in the Class Action Filed on Behalf of Gossamer Bio, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 20, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) alleging that the Company violated federal securities laws.The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in ...
- 05/20/2020
|
GOSSAMER DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Gossamer Bio, Inc. To Contact The Firm
- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company")(NASDAQ:GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 05/20/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Gossamer Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 2, 2020 - GOSS
- New York, New York--(Newsfile Corp. - May 19, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer") The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February ...
- 05/19/2020
|
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 19, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" ...
- 05/19/2020
|
Why Gossamer Bio Stock Is Tumbling Today
- Shares of Gossamer Bio (NASDAQ: GOSS) were tumbling 16.4% lower as of 11:55 a.m. EDT on Tuesday. The decline came after the company announced the pricing of a secondary stock offering of more than 9.4 million shares and $200 million in convertible senior notes due in 2027. Gossamer plans to offer the additional stock at a price of $13.25 per share.
- 05/19/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
- NEW YORK, NY / ACCESSWIRE / May 19, 2020 / Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS). Such investors ...
- 05/19/2020
|
Lawsuits Filed Against GOSS, BBBY and GRPN - Jakubowitz Law Pursues Shareholders Claims
- NEW YORK, NY / ACCESSWIRE / May 19, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
- 05/19/2020
|
Gossamer Bio Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its underwritten public offering of 9,433,963 shares of its common stock at a price to the public of $13.25 per share and the pricing of $200.0 million aggregate principal amount of its 5.00% convertible senior notes due 2027. The aggregate gross proceeds to Gossamer from the offerings, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $325.0 million.
- 05/19/2020
|
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 18, 2020 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" ...
- 05/19/2020
|
The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 18)
ADC Therapeutics SA (NYSE:...
- 05/19/2020
|
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027
- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it intends to offer, subject to market and other conditions, shares of common stock and convertible senior notes due 2027 (the "notes") in separate concurrent underwritten public offerings registered under the Securities Act of 1933, as amended.
- 05/18/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ANAB, MESA and GOSS
- NEW YORK, NY / ACCESSWIRE / May 18, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment.
- 05/18/2020
|
GOSS & ZM INVESTOR NOTIFICATION: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
- NEW YORK, NY / ACCESSWIRE / May 18, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...
- 05/18/2020
|
DEADLINE APPROACHING: Block & Leviton Filed the First Lawsuit Against Gossamer Bio, Inc. for Securities Fraud; Shareholders Who Have Lost Money Should Contact the Firm
- BOSTON, MA / ACCESSWIRE / May 18, 2020 / Block & Leviton LLP ( www.blockesq.com ), a national securities litigation firm, reminds shareholders that it filed the first class action lawsuit on behalf of ...
- 05/18/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GOSS, LBRT and GSX
- NEW YORK, NY / ACCESSWIRE / May 18, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 05/18/2020
|
Gossamer Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Gossamer Bio, Inc. To Contact The Firm
- New York, New York--(Newsfile Corp. - May 18, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi logoIf you invested in Gossamer stock or options between February 8, 2019 and December ...
- 05/18/2020
|
CLASS ACTION UPDATE for GOSS, LBRT and LOPE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / May 18, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 05/18/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
- Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 05/17/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MESA, GOSS and SERV
- NEW YORK, NY / ACCESSWIRE / May 15, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 05/15/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
- NEW YORK, NY / ACCESSWIRE / May 15, 2020 / Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS). Such investors ...
- 05/15/2020
|
Gossamer Bio Inc (GOSS) Q1 2020 Earnings Call Transcript
- Ladies and gentlemen, thank you for standing by and welcome to the Gossamer Bio Incorporated Customer Q1 Earnings Conference Call. Earlier this afternoon Gossamer Bio issued a press release announcing its financial results for the first quarter ended March 31, 2020 in addition to providing a corporate update.
- 05/13/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XP, MESA and GOSS
- NEW YORK, NY / ACCESSWIRE / May 13, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 05/13/2020
|
GOSS & ZM INVESTOR NOTIFICATION: Bronstein, Gewirtz & Grossman LLC Updates Investors of Class Actions and Encourages Investors to Contact the Firm
- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.
- 05/13/2020
|
LAWSUITS FILED AGAINST XP, MESA and GOSS - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
- NEW YORK, NY / ACCESSWIRE / May 13, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
- 05/13/2020
|
FAST-APPROACHING DEADLINE: Block & Leviton Filed the First Lawsuit Against Gossamer Bio, Inc. for Securities Fraud; Shareholders Who Have Lost Money Should Contact the Firm
- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, reminds shareholders that it filed the first class action lawsuit on behalf of shareholders against Gossamer Bio, Inc. (GOSS) and certain of its officers and directors for securities fraud. Investors who purchased Gossamer shares between February 8, 2019 and December 13, 2019, should contact the firm for a free case evaluation. Gossamer is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics in the areas of immunology, inflammation, and oncology.
- 05/13/2020
|
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) * Acceleron Pharma Inc (NASDAQ: XLRN)(reacted to its first-quarter results) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Arvinas Inc (NASDAQ: ARVN) * Ascendis Pharma A/S (NASDAQ: ASND) * AtriCure Inc. (NASDAQ: ATRC) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * BioSig Technologies Inc (NASDAQ: BSGM) * BIO-TECHNE Corp (NASDAQ: TECH) * BioXcel Therapeutics Inc (NASDAQ: BTAI)(announced its first-quarter results) * Black Diamond Therapeutics Inc (NASDAQ: BDTX)(reacted to its first-quarter results) * ChemoCentryx Inc (NASDAQ: CCXI)(reacted to its first-quarter results) * Cytokinetics, Inc. (NASDAQ: CYTK) * CytomX Therapeutics Inc (NASDAQ: CTMX) * Cytosorbents Corp (NASDAQ: CTSO)(announced European approval for Cytosorb) * Emergent Biosolutions Inc (NYSE: EBS) * Exelixis, Inc. (NASDAQ: EXEL) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Halozyme Therapeutics, Inc. (NASDAQ: HALO)(announced its first-quarter results) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Imara Inc (NASDAQ: IMRA) * Immunomedics, Inc. (NASDAQ: IMMU) * Immunovant Inc (NASDAQ: IMVT) * Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) * Keros Therapeutics Inc (NASDAQ: KROS) * MacroGenics Inc (NASDAQ: MGNX) * Masimo Corporation (NASDAQ: MASI) * Mersana Therapeutics Inc (NASDAQ: MRSN) * Minerva Neurosciences Inc (NASDAQ: NERV) * Moderna Inc (NASDAQ: MRNA)(received Fast Track designation for its coronavirus vaccine) * Myokardia Inc (NASDAQ: MYOK) * Natera Inc (NASDAQ: NTRA) * NGM Biopharmaceuticals Inc (NASDAQ: NGM) * Novavax, Inc. (NASDAQ: NVAX)(announced grant up to $384 million CEPI funding for its coronavirus vaccine progeam) * Protagonist Therapeutics Inc (NASDAQ: PTGX)(priced its 7 million common stock offering) * Repligen Corporation (NASDAQ: RGEN) * Scpharmaceuticals Inc (NASDAQ: SCPH) * TG Therapeutics Inc common stock (NASDAQ: TGTX)(reacted to its first-quarter results) * Translate Bio Inc (NASDAQ: TBIO) * United Therapeutics Corporation (NASDAQ: UTHR) * Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) * West Pharmaceutical Services Inc. (NYSE: WST) * Zai Lab Ltd (NASDAQ: ZLAB) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 12) * Genfit SA (NASDAQ: GNFT) ( announced NASH candidate flunked a late-stage study)Stocks In Focus Bristol-Myers, Bluebird bio's BLA For Multiple Myeloma Immunotherapy Rejected By FDA Bristol-Myers Squibb Co (NYSE: BMY) and bluebird bio Inc (NASDAQ: BLUE) said they have received a Refusal to File letter from the FDA regarding the BLA for idecabtagene vicleucel for patients with heavily pre-treated relapsed and refractory multiple myeloma. The submission was in March.The FDA deemed the Chemistry, Manufacturing and Control module of the BLA requires further detail to complete the review and had not requested additional data. Bristol-Myers Squibb said it's planning to resubmit the BLA no later than the end of JulyEdap Signs Deal To Distribute Exact Imaging's Mico-ultrasound Diagnostic Devices Edap Tms SA (NASDAQ: EDAP) announced the signing of an exclusive worldwide distribution agreement with Exact Imaging to distribute the latter's micro-ultrasound diagnostic devices alongside its Focal One high intensity focused ultrasound treatment solution."The combination of these technologies represents the most complete end-to-end solution, from diagnosis through treatment, available to urologists today," Edap said.The stock rallied 15.47% to $2.50 in after-hours trading.Merck Unit To Acquire US Rights of Sentinel's Animal Parasiticide Products For $400M Merck & Co., Inc.'s (NYSE: MRK) Animal Health unit signed a definitive agreement to acquire the U.S. rights to SENTINEL FLAVOR TABS and SENTINEL SPECTRUM Chews, both parasiticide products, in the Companion Animal category for $400 million. The deal is expected to close in the middle of 2020.In after-hours trading, the stock fell 1.53% to $76.01.Genocea Highlights Advantages Of Neoantigen T-Cell Therapy Targeting Cancers Following a KOL symposium, Genocea Biosciences Inc (NASDAQ: GNCA) said its GEN-011 embraces the advantages of TIL therapy while improving on its limitations. The company also said it has established a robust, scalable manufacturing process, PLANET, using peripheral blood T cells to ensure greater activity and durability for larger patient populations."In GEN-011, Genocea is creating a transformative ATLAS-enabled, peripheral blood-derived T cell therapy," said Chip Clark, Genocea's CEO.The company said it expects to file an IND in the second quarter and release initial clinical data in the first half of 2020. The stock climbed 21.48% to $3.28 in after-hours trading.Aerpio Amends Licensing Agreement With Gossamer For Inflammatory Bowel Disease Drug; Gossamer Reports Positive Phase 1 Results Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) announced a restructuring of the licensing deal it has with a subsidiary of Gossamer Bio Inc (NASDAQ: GOSS) for its HIF-1 alpha stabilizer GB004, which is being developed for inflammatory bowel disease. The amended terms call for an immediate payment of $15 million to Aerpio and a total of $90 million in milestone payments related to regulatory approvals and commercial sales.Aerpio is also eligible to receive tiered royalties on sales of licensed products at percentages ranging from the low to mid-single digits.Meanwhile, Gossamer announced promising top-line results from its Phase 1b study of GB004 in patients with active mild-to-moderate ulcerative colitis.In after-hours trading, Aerpio shares soared 44.45% to 90 cents and Gossamer Bio gained 2.61% to $16.30.Mylan Signs Non-Exclusive Licensing to Manufacture and Supply Gilead's Remdesivir In Low- and Mid-Income Countries Mylan NV (NASDAQ: MYL) announced a non-exclusive licensing agreement with Gilead Sciences, Inc. (NASDAQ: GILD), which provides for the former acquiring the rights to manufacture and distribute the latter's antiviral drug remdesivir in 127 low- and middle-income countries, including India.Mylan also said it's confident it will be able to develop and make available a bioequivalent version of remdesivir in the coming months.Separately, Indian pharmaceutical company Cipla announced a non-exclusive licensing agreement with Gilead to manufacture remdesivir.In after-hours trading, Mylan shares rose 3.57% to $16.81.Earnings Adaptive Biotechnologies Corp's (NASDAQ: ADPT) first-quarter revenues climbed 65% to $20.9 million. The net loss per share narrowed from $1.45 cents to 25 cents. The company withdrew its 2020 guidance. The results trailed expectations.View more earnings on IBBThe stock fell 9.35% to $34.50 in after-hours trading.Opiant Pharmaceuticals Inc (NASDAQ: OPNT) reported first-quarter revenues of $4.3 million, up 12% year-over-year. The net loss per share narrowed from 44 cents to 40 cents. The results were below expectations.The company also said it expects to file NDA for its lead drug OPNT003 - nasal nalmefene, for opioid overdose - in early 2021.In pre-market trading Wednesday, the stock declined 7.60% to $10.82.aTyr Pharma Inc (NASDAQ: LIFE) reported revenues of $8.1 million in the first quarter of 2020 compared to no revenues a year-ago. Revenues consisted primarily of licensing revenue from the Kyorin Agreement. The company reported a profit of 25 cents per share compared to a loss of $2.54 cents per share a year ago. The results exceeded expectations.The stock gained 7.49% to $4.16 in pre-market trading.Clearpoint Neuro Inc (NASDAQ: CLPT) reported a loss of 13 cents per share on revenues of $3.12 million for the first quarter of 2020. In the year-ago period, the company reported a loss of 11 cents per share on revenues of $2.47 million.The stock retreated 9.60% to $3.20 in pre-market trading.Offerings Myokardia priced its underwritten public offering of 5.25 million shares at $105.00 per share. The offering is expected to close on or about May 15.Insulet Corporation (NASDAQ: PODD) priced its $500 million common stock registered underwritten offering at $211.00 per share, in which the company will sell 2.37 million sharesIn after-hours trading, the stock slipped 3.94% to $212.Oyster Point Pharma Inc (NASDAQ: OYST) said it has commenced an underwritten public offering of 2.5 million shares of its common stock. All the shares are being offered by the company.The stock fell 6.74% to $30.01 in after-hours trading.On The Radar Earnings • PDS Biotechnology Corp (NASDAQ: PDSB) (before the market open) • Veru Inc (NASDAQ: VERU) (before the market open) • Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) • Applied Genetic Technologies Corp (NASDAQ: AGTC) (before the market open) • BioLife Solutions Inc (NASDAQ: BLFS) (after the close) • DiaMedica Therapeutics Inc (NASDAQ: DMAC) (after the close) • Viela Bio Inc (NASDAQ: VIE) (after the close) • Biocept Inc (NASDAQ: BIOC) (after the close) • Eyenovia Inc (NASDAQ: EYEN) (after the close) • Edap Tms SA (NASDAQ: EDAP) (after the close) • RA Medical Systems Inc (NYSE: RMED) (after the close) • TRACON Pharmaceuticals Inc (NASDAQ: TCON) (after the close) • Brickell Biotech Inc (NASDAQ: BBI) (after the close) • HTG Molecular Diagnostics Inc (NASDAQ: HTGM) (after the close)Clinical Readouts Avrobio Inc (NASDAQ: AVRO) is scheduled to make an oral presentation at the American Society of Gene and Cell Therapy virtual meeting new data from the Phase 2 trial of AVR-RD-01 for Fabry. The company will also make an oral presentation of new data from the collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 in cystinosis.
- 05/13/2020
|
Gossamer Bio, Inc. (GOSS) CEO Sheila Gujrathi on Q1 2020 Results - Earnings Call Transcript
- Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2020 Earnings Conference Call May 12, 2020 16:30 ET Company Participants Bryan Giraudo - Chief Financial Officer Sheila Gujr
- 05/13/2020
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 12, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020.
- 05/13/2020
|
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
- 05/13/2020
|
Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)
- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced a restructuring of their licensing deal with a wholly owned subsidiary of Gossamer Bio Inc., GB004, Inc. (“Gossamer Bio”) (GOSS), for its HIF-1 alpha stabilizer, GB004. The deal continues the collaboration between Gossamer Bio’s strong gastrointestinal (“GI”) development team and Aerpio’s management team.
- 05/12/2020
|
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the first quarter 2020 and provided a corporate update.
- 05/12/2020
|
SHAREHOLDER ALERT: GOSS SERV HALL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / May 12, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss ...
- 05/12/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
- NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS). Such investors ...
- 05/12/2020
|
SHAREHOLDER ALERT: GOSS ZM IQ: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / May 11, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss ...
- 05/12/2020
|
SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 11, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020.
- 05/12/2020
|
The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 11)
Acceleron Pharma Inc (NASDAQ...
- 05/12/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XP, GOSS and BIDU
- NEW YORK, NY / ACCESSWIRE / May 10, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 05/10/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
- Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 05/10/2020
|
CLASS ACTION UPDATE for GOSS, SERV and DNK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / May 10, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 05/10/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 8, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020.
- 05/09/2020
|
New Strong Buy Stocks for May 8th
- New Strong Buy Stocks for May 8th
- 05/08/2020
|
Gossamer Bio to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 12, 2020
- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its first quarter 2020 financial results on Tuesday, May 12, 2020.
- 05/08/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MESA, NCLH and GOSS
- NEW YORK, NY / ACCESSWIRE / May 7, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders ...
- 05/07/2020
|
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 7, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020.
- 05/07/2020
|
LAWSUITS FILED AGAINST DOYU, GOSS and LBRT - Jakubowitz Law Pursues Shareholders Claims
- NEW YORK, NY / ACCESSWIRE / May 7, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
- 05/07/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
- NEW YORK, NY / ACCESSWIRE / May 7, 2020 / Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS). Such investors ...
- 05/07/2020
|
GOSSAMER DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Gossamer Bio, Inc. To Contact The Firm
- NEW YORK, NY / ACCESSWIRE / May 6, 2020 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company") (GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Gossamer stock or options between February 8, 2019 and December 13, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/GOSS.
- 05/06/2020
|
LAWSUITS Filed Against ANAB, GOSS and IQ - JAKUBOWITZ LAW Pursues Shareholders Claims
- NEW YORK, NY / ACCESSWIRE / May 6, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased ...
- 05/06/2020
|
SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 5, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020.
- 05/06/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
- Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 05/05/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GOSS, IQ and DNK
- NEW YORK, NY / ACCESSWIRE / May 5, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders ...
- 05/05/2020
|
GOSS SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
- NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the ...
- 05/05/2020
|
CLASS ACTION UPDATE for INO, GOSS and BIDU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 05/05/2020
|
Lawsuit for Investors in Gossamer Bio, Inc. (NASDAQ: GOSS) Shares Announced by Shareholders Foundation
- SAN DIEGO, CA / ACCESSWIRE / May 5, 2020 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ:GOSS shares. Investors, who purchased shares of Gossamer ...
- 05/05/2020
|
CLASS ACTION UPDATE for XP, GOSS and FITB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / May 4, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested ...
- 05/04/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
- NEW YORK, NY / ACCESSWIRE / May 4, 2020 / Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS). Such investors ...
- 05/04/2020
|
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / May 1, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020.
- 05/01/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of GOSS, ZM and SERV
- NEW YORK, NY / ACCESSWIRE / May 1, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders ...
- 05/01/2020
|
SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 30, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020.
- 05/01/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DOYU, GOSS and BIDU
- NEW YORK, NY / ACCESSWIRE / April 30, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 04/30/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
- NEW YORK, NY / ACCESSWIRE / April 30, 2020 / Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ:GOSS). Such investors ...
- 04/30/2020
|
CLASS ACTION UPDATE for DOYU, GOSS and DNK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
- NEW YORK, NY / ACCESSWIRE / April 30, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders ...
- 04/30/2020
|
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 30, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of §§10(b) and 20(a) of the Securities
- 04/30/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CRON, GOSS and FITB
- NEW YORK, NY / ACCESSWIRE / April 29, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders ...
- 04/29/2020
|
Shareholder Alert: Robbins LLP Reminds Investors It Is Investigating Gossamer Bio, Inc. (GOSS) on Behalf of Shareholders
- Shareholder rights law firm Robbins LLP reminds investors it is investigating Gossamer Bio, Inc. (NYSE: GOSS) for potential violations of federal securities laws and breaches of fiduciary duty by its board members and executive officers. In its initial public offering, Gossamer offered approximately 19.8 million shares at $19.00 per share, raising gross proceeds of $317.4 million. Gossamer's leading product is its GB001 drug, which is a DP2 antagonist drug for the treatment of asthma. However, on December 16, 2019, Novartis announced it was terminating the development of its similar DP2 antagonist drug for asthma after it failed a pair of phase 3 clinical trials. On this news, Gossamer's stock plummeted 37% to close at $15.96 per share, representing a 16% decline from its IPO price.
- 04/29/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XP, ANAB and GOSS
- NEW YORK, NY / ACCESSWIRE / April 28, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 04/28/2020
|
SHAREHOLDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 28, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" ) or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2020.
- 04/28/2020
|
GOSS & TUFN INVESTOR NOTIFICATION: Bronstein, Gewirtz & Grossman LLC Updates Investors of Class Actions and Encourages Investors to Contact the Firm
- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.
- 04/28/2020
|
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MESA, GOSS and BIDU
- NEW YORK, NY / ACCESSWIRE / April 28, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders ...
- 04/28/2020
|
LOOMING DEADLINE: Block & Leviton Filed the First Lawsuit Against Gossamer Bio, Inc. for Securities Fraud; Shareholders Who Have Lost Money Should Contact the Firm
- BOSTON, April 28, 2020 -- Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, reminds shareholders that it filed the first class action lawsuit.
- 04/28/2020
|
Notice of Lead Plaintiff Deadline for Shareholders in the Gossamer Bio, Inc. Securities Class Action Lawsuit
- Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Southern District of California on behalf of purchasers of Gossamer Bio, Inc. (NASDAQ:GOSS) common stock between February 8, 2019 and December 13, 2019 (the "Class Period") and/or those who acquired Gossamer stock pursuant or traceable to the Company’s February 8, 2019 initial public offering ("IPO"). The case is captioned Kuhne v. Gossamer Bio, Inc., No. 20-cv-00649, and is assigned to Judge Dana M. Sabraw. The Gossamer Bio securities class action lawsuit charges Gossamer, certain of its officers and directors, and the underwriters of its IPO with violations of the Securities Exchange Act of 1934 and/or the Securities Act of 1933.
- 04/28/2020
|
SHAREHOLDER ALERT: MESA GOSS BBBY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
- NEW YORK, NY / ACCESSWIRE / April 27, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss, ...
- 04/27/2020
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSS
- Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- 04/27/2020
|
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CAN, GOSS and FITB
- NEW YORK, NY / ACCESSWIRE / April 27, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...
- 04/27/2020
|
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 27, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ:GOSS) for violations of §§10(b) and 20(a) of the Securities
- 04/27/2020
|
